Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 601–700 of 999
Vellas, B. J. (2021) · The journal of nutrition health & aging · doi:10.1007/s12603-021-1657-8 · Cited by 14
Self-citationXu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14238 · Cited by 11
Advances in Neurorestoratology—Current status and future developments
Huang, H., Ramón‐Cueto, A., Masri, W. E., Moviglia, G. A., Saberi, H., Sharma, H. S., Otom, A. H., Chen, L., Siniscalco, D., & Sarnowska, A. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.04.003 · Cited by 12
Zhang, M., Zheng, H., He, J., & Zhang, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21800 · Cited by 18
“Currently, the drugs used to treat AD are mainly single-target drugs that only delay the symptoms of AD to a certain extent and have a number of side effects [27,28].”
BackgroundMore failure with solanezumab – this time in preclinical Alzheimer’s disease
Doggrell, S. A. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2325551 · Cited by 12
“One of the suggestions for the failure was that the dose of solanezumab was too low to reach the levels that were high enough in the brain to give meaningful results [13].”
BackgroundSchreiner, T. G., Croitoru, C. G., Hodorog, D. N., & Cuciureanu, D. I. (2024) · Biomedicines · doi:10.3390/biomedicines12051096 · Cited by 15
“Regarding second-generation medication, Solanezumab was associated with four types of adverse events, which occurred more frequently compared to a placebo, namely vitamin D deficiency, spinal osteoarthritis, nasal congestion, and dysuria [62].”
BackgroundAlzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Hroudová, J., & Fišar, Z. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111069 · Cited by 13
Ye, M., Yang, Q., Zhang, L., Song, H., Fu, Q., Qian, J., Xie, H., & Yuan, A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1394499 · Cited by 12
“Recently, two large-scale clinical trials on drug prevention and treatment of Alzheimer’s disease ended in failure, and one phase III clinical trial had to be terminated because of no efficacy (8, 9).”
BackgroundOrtiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 16
“…AD II [194,195] ABvac40 Mild to moderate AD II [196] Solanezumab Mild to moderate AD, prodromal AD, participants at risk of memory loss III [197,198] Gantenerumab Mild AD, prodromal to mild AD, early AD III [123,199,200] Aducanumab Early AD III [201–203] Crenezumab Prodromal to mild AD III…”
Gao, S., Dai, H., Hao, Q., Song, J., Ji, K., Xu, H., Chen, G., & Lu, J. G. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06584-2 · Cited by 23
“The change in MMSE scores was consistent with the change in the 14-item cognitive subscale of the Alzheimer’s Disease [30].”
Mullane, K., & Williams, M. J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.004 · Cited by 14
Liu, J., & Wang, L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1620106 · Cited by 14
Herring, A., Kurapati, N. K., Krebs, S., Grammon, N., Scholz, L. M., Voss, G., Miah, M. R., Budny, V., Mairinger, F. D., Haase, K., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12687 · Cited by 17
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 15
“However, the failure of amyloid reduction-based therapies in patients with cognitive impairment suggests interventions are too late (Honig et al. 2018; Makin 2018).”
BackgroundKamei, N., Hashimoto, A., Tanaka, E., Murata, K., Yamaguchi, M., Yokoyama, N., Kato, M., Oki, K., Saito, T., Saido, T. C., et al. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01117-6 · Cited by 13
“However, most candidates have been dropped from clinical trials due to insufficient efficacy [4, 6].”
BackgroundWang, G., Li, Y., Xiong, C., McDade, E., Clifford, D. B., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., Hassenstab, J. J., Benzinger, T. L. S., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12367 · Cited by 13
Gautam, A. S., Pandey, S. K., Lasure, V., Dubey, S., & Singh, R. K. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2227378 · Cited by 14
Development of a quality of life questionnaire for nursing home residents in mainland China
Xu, D., Gao, J., Chen, L., Mou, H., Wang, X., Ling, J., & Wang, K. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02180-2 · Cited by 12
“Residents were categorized as having moderate or mild/no cognitive impairment, which was measured using the MMSE [35, 36].”
MethodKapoor, A., ONDRI Investigators, Bartha, R., Black, S. E., BORRIE, M. J., Freedman, M., Gao, F., Herrmann, N., Mandzia, J. L., Ozzoude, M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191097 · Cited by 13
“3 NCT01900665 [42] 2129 Drug: Solanezumab ADAS-Cog Mild x x”
BackgroundSelf-citationLi, X., Li, X., Liu, Q., & Cheng, Y. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01528-5 · Cited by 13
Yuan, X., Wang, L., Tandon, N., Sun, H., Tian, J., Du, H., Pascual, J. M., & Guo, L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200594 · Cited by 12
Yang, Y., Diao, Y., Jiang, L., Li, F., Chen, L., Ni, M., Wang, Z., & Fang, H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.018 · Cited by 11
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
Tian, J., Shi, J., Ni, J., Wei, M., Zhang, X., Chen, K., & Wang, Y.-Y. (2019) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-019-3066-y · Cited by 11
Fletcher, J. R. (2020) · Sociology of Health & Illness · doi:10.1111/1467-9566.13054 · Cited by 13
Effects of Current Psychotropic Drugs on Inflammation and Immune System
Bhatt, S., Dhar, A. K., Samanta, M. K., & Suttee, A. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_18 · Cited by 13
Lannfelt, L. (2023) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v128.10316 · Cited by 14
“…of trial data revealed a slowing of cognitive decline in individuals with mild AD (44), and an open-label extension study in patients who had completed Phase 3 trials suggested that solanezumab produced a cognitive benefit consistent with a treatment effect on the underlying AD pathology (46).”
ResultKuriyama, M., Wang, C. F., Nagase, T., Sohma, Y., Kanai, M., Hori, Y., & Tomita, T. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00548 · Cited by 12
“For example, bapineuzumab targets fi brillar and soluble A β [25], while solanezumab binds to the central domain of soluble monomeric A β [26].”
Panda, P., Mohanty, S., Gouda, S. R., Baral, T. C., Mohanty, A., Nayak, J., & Mohapatra, R. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2472773 · Cited by 12
“Hence, drugs that would not only repair tau pathology but also show a good promise of the effects would play a significant role in the treatment of Alzheimer’s disease by targeting tau pathology [52].”
Prevention of Alzheimer's Disease in Chinese Populations: Status, Challenges and Directions
Feng, L., Li, J., Yu, J., Zhang, C., Yang, B., Vellas, B. J., & Li, C. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.14 · Cited by 11
“n January 2018, the investigators from Eli Lily’s EXPEDITION3 trial published their negative findings of a large phase 3 trial on the antibody Solanezumab (1).”
InfluentialSelf-citationEffect of Feru‐guard 100M on amyloid‐beta deposition in individuals with mild cognitive impairment
Matsuyama, K., Yamamoto, Y., & Sora, I. (2020) · Psychogeriatrics · doi:10.1111/psyg.12581 · Cited by 13
Lye, S., Aust, C. E., Griffiths, L. R., & Fernandez, F. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117332 · Cited by 11
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Sahib, S., Tian, Z. R., Bryukhovetskiy, I., Manzhulo, I., Menon, P. K., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.04.008 · Cited by 12
Alzheimer’s dementia or Alzheimer’s disease – What’s the difference and why should we care?
Gibbs, D. M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101779 · Cited by 11
“Although the anti-amyloid monoclonal antibody solanezumab failed to slow cognitive impairment in subjects with mild dementia due to Alzheimer’s disease, (Honig et al., 2018) a long term,”
The Potential of a Stratified Approach to Drug Repurposing in Alzheimer’s Disease
Anderson, C., Bucholc, M., McClean, P. L., & Zhang, S. (2023) · Biomolecules · doi:10.3390/biom14010011 · Cited by 16
“Solanezumab, a G1 monoclonal antibody that binds to A β , failed to significantly reduce cognitive decline in a phase III clinical trial [179].”
BackgroundDevelopment of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns
Lu, D., Dou, F., & Gao, J. (2023) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01215 · Cited by 14
Liu‐Seifert, H., Siemers, E., Sundell, K., Mynderse, M., Cummings, J. L., Mohs, R. C., & Aisen, P. S. S. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.22 · Cited by 12
“EXPEDITION 3 was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of the effects of solanezumab (9).”
BackgroundSelf-citationYue, S., He, T., Li, B., Qu, Y., Peng, H., Chen, J., Lei, M., Chen, C., & Wu, W. (2019) · Trials · doi:10.1186/s13063-019-3607-x · Cited by 13
Pirolla, N. F. F., Batista, V. S., Viegas, F. P. D., Gontijo, V. S., McCarthy, C. R., Viegas, C., & Nascimento-Júnior, N. M. (2020) · Current Drug Targets · doi:10.2174/1389450121999200819144544 · Cited by 13
Still grasping at straws: donanemab in Alzheimer’s disease
Doggrell, S. A. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1948010 · Cited by 12
Immune modulations and immunotherapies for Alzheimer’s disease: a comprehensive review
Mahdiabadi, S., Momtazmanesh, S., Perry, G. L., & Rezaei, N. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0092 · Cited by 13
Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
Weigand, A. J., Edwards, L., Thomas, K. R., Bangen, K. J., Bondi, M. W., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac272 · Cited by 14
Schultz, S. A., Shirzadi, Z., Schultz, A. P., Liu, L., Fitzpatrick, C. D., McDade, E., Barthélemy, N. R., Renton, A. E., Esposito, B. T., Joseph‐Mathurin, N., et al. (2023) · Aging Cell · doi:10.1111/acel.13871 · Cited by 10
“However, reductions in β - amyloid burden are not necessarily accompanied by corresponding improvements in rates of cognitive and functional decline (Doody et al., 2013; Henley et al., 2019; Honig et al., 2018; Salloway et al., 2021; Sevigny et al., 2016 ).”
The Mode of Action of an Anti-Oligomeric Amyloid β-Protein Antibody Affects its Protective Efficacy
Zhang, Y., Huai, Y., Zhang, X., Song, C., Cai, J., & Zhang, Y. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9955-6 · Cited by 11
The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development
Milne, R. (2019) · New Genetics and Society · doi:10.1080/14636778.2019.1637718 · Cited by 11
“Nevertheless, as described in the introduction, solanezumab again failed to show a significant effect in this population (Honig et al. 2018).”
BackgroundKinetic fingerprints differentiate anti-Aβ therapiesPreprint
Linse, S. S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Šileikis, E., Lundquist, M., Qian, F., O’Malley, T. T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/815308 · Cited by 10
New Approaches to the Treatment of Alzheimer’s Disease
Kruk-Słomka, M., Kuceł, D., Małysz, M., Machnikowska, A., Orzelska‐Górka, J., & Biała, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081117 · Cited by 14
“The decision by the EMA is still pending (status as of June 2025) [12,24] (Table 1).”
InfluentialYao, J., & Chen, S. R. W. (2023) · The Journal of Physiology · doi:10.1113/jp283824 · Cited by 10
“Unfortunately, the results of most major A β -targeted clinical trials have been dismal (Castellani et al., 2019; Chakroborty & Stutzmann, 2014; Honig et al., 2018; Karran et al., 2011; Sun et al., 2018), highlighting the urgent need to develop new non-A β -targeted AD therapeutic strategies.”
The amyloid-β peptide: Guilty as charged?
Murphy, M. P., Buzinova, V. A., & Johnson, C. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166945 · Cited by 14
Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review
Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 16
Triumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Malpetti, M., Rathore, S., Iaccarino, L., Joie, R. L., Tronchin, G., Wessels, A. M., Sims, J. R., Pontecorvo, M. J., Shcherbinin, S., & Rabinovici, G. D. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01868-7 · Cited by 14
“We included participants enrolled either in observational flortaucipir clinical development studies (AV1451-A05: NCT02016560 [2]) or in interventional clinical trials (EXPEDITION-3: NCT01900665 [16], and AMA-RANTH: NCT02245737 [17]) conducted at Eli Lilly and Company.”
Бачурин, С. О., Bovina, E. V., & Ustyugov, A. A. (2018) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00015 · Cited by 11
Alzheimer’s Disease Progression in the 5×FAD Mouse Captured with a Multiplex Gene Expression Array
Gatt, A. P., Whitfield, D., Ballard, C. G., Doherty, P., & Williams, G. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190805 · Cited by 9
“E-mail:gareth.2.williams@kcl.ac.uk. antibody therapies [1, 2] and BACE inhibitors [3], has led many groups to explore non-target-based techniques [4].”
Cogo‐Moreira, H., Krance, S. H., Black, S. E., Herrmann, N., Lanctôt, K. L., MacIntosh, B. J., Eid, M., & Swardfager, W. (2020) · Assessment · doi:10.1177/1073191120915273 · Cited by 10
Jiang, L., Sun, Q., Li, L., Lu, F., & Liu, F. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00555 · Cited by 10
Chen, L., Zhou, Z., Zhang, Y., Pan, J., Wang, K., & Wang, H. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00372d · Cited by 10
Liu, C., & Guo, X. (2022) · Pharmaceuticals · doi:10.3390/ph15111424 · Cited by 10
“There are no specific treatments available [36].”
Research Progress of Targeting Neuro-Immune Inflammation in the Treatment of Alzheimer's Disease
Chen, H., Deng, C., Meng, Z., & Meng, S. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2711312 · Cited by 10
“The humanized monoclonal antibody solanezumab is used to increase the clearance of soluble A β peptide in the brain [47].”
MethodConsequence of Dementia and Cognitive Impairment by Primary Nucleation Pathway
Singh, A., Ansari, V. A., Ansari, T. M., Hasan, S. M., Ahsan, F., Singh, K., Wasim, R., Maheshwari, S., & Ahmad, A. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2052-8462 · Cited by 10
Alternative Approaches to the Search for Alzheimer’s Disease Treatments
Lien, E. J. C., Adams, J. D., Jr., Lien, L. L.-M., & Law, M. (2018) · J — Multidisciplinary Scientific Journal · doi:10.3390/j1010002 · Cited by 10
Xu, X., Lü, P., Wang, J., Xu, F., Liang, L., Wang, C., Niu, Y., & Xu, P. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13489 · Cited by 11
“The challenges associated with the β- amyloid hypothesis have resulted in continual failures (Egan et al., 2018; Honig et al., 2018; Timmers et al., 2018).”
BackgroundThe Economic Burden of Alzheimer’s Disease in Zhejiang Province
Yu, E., Liao, Z., Fan, W., Hu, W., Tian, G., Chen, K., Chen, S., Hua, H., Zheng, H., Fang, X., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201285 · Cited by 11
Liu, Y., Cong, L., Han, C., Li, B., & Dai, R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201127104539 · Cited by 11
He, Z., Zheng, L. P., Zhao, X., Li, X., Xue, H., Zhao, Q., Ren, B., Li, N., Ni, J., Zhang, Y., et al. (2022) · Biological Trace Element Research · doi:10.1007/s12011-021-02938-1 · Cited by 10
“Previous efforts to develop antiAD drugs, such as solanezumab, have not been successful [2], suggesting that AD is a multifaceted disease and may be inappropriate using single-modal treatments.”
BackgroundWessels, A. M., Belger, M. A., Johnston, J. A., Yu, Y., Rentz, D. M., Dowsett, S. A., & Chandler, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220303 · Cited by 12
A comparison of advanced semi-quantitative amyloid PET analysis methods
Peira, E., Poggiali, D., Pardini, M., Barthel, H., Sabri, O., Morbelli, S. D., Cagnin, A., Chincarini, A., & Cecchin, D. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05846-1 · Cited by 12
Zhang, L., Xu, J., Guo, J., Wang, Y., & Wang, Q. (2023) · Molecules · doi:10.3390/molecules28155846 · Cited by 11
“In addition, neurotransmitter disorders [10], hormone imbalances [11], and genetic components [12] are also considered to play important roles in the occurrence and development of AD.”
BackgroundQuerfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons
Tohumeken, Ş., Deme, P., Yoo, S. W., Gupta, S., Rais, R., Slusher, B. S., & Haughey, N. J. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.105987 · Cited by 9
Kim, H.-R., Shin, H.-Y., Yim, T.-B., Jahng, G., Jin, C., Kwon, S.-W., Cho, S.-Y., Park, S.-U., Jung, W., Moon, S., et al. (2023) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2023/4846770 · Cited by 8
“In contrast, it has been reported that among patients with mild AD, higher initial MMSE-1 scores are associated with lower drug treatment results [44].”
Peng, D., Xu, S., Zou, T., Wang, Y., Ouyang, W., Zhang, Y., Dong, C., Li, D., Guo, J., Shen, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03126-9 · Cited by 11
Portal, B., Södergren, M., Borrell, T. P. I., Giraud, R., Metzendorf, N. G., Hultqvist, G., Nilsson, P., & Lindskog, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231461 · Cited by 10
Alzheimer's Disease and Vascular Dementia, Connecting and Differentiating Features
Hurła, M., Banaszek, N., Kozubski, W. P., & Dorszewska, J. (2024) · Current Alzheimer Research · doi:10.2174/0115672050319219240711103459 · Cited by 10
Amyloid-Directed Antibodies: Past, Present, and Future
Noorda, K., Noorda, K. J., Sabbagh, M. N., Bertelson, J. A., Singer, J., & Decourt, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240189 · Cited by 11
“However, after enrolling more than 2000 participants, this trial was discontinued in 2016 due to a lack of evidence supporting a reduction in cognitive decline in AD patients by week 80 [35].”
Abel, A., Chambers, A., Fill, J. A., Reiske, H., Lu, M., Morris, A., Faya, P., Beck, R. C., Pontecorvo, M. J., Collins, E. C., et al. (2025) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae155 · Cited by 11
Self-citationSordu, P., Alaylıoğlu, M., Samancı, B., Bulu, E., Güleç, Z. E. K., Bılgıç, B., Hanagasi, H. A., Gurvit, H. I., Ulutin, T., Dursun, E., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329540 · Cited by 11
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., Initiative, A. D. N., Weiner, M. W., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213490 · Cited by 10
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 11
Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer’s Disease
Strużyńska, L., Adamiak, K., & Sidoryk‐Wȩgrzynowicz, M. (2026) · Biomolecules · doi:10.3390/biom16040595 · Cited by 9
Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202 · Cited by 10
Son, S. H., Do, J. M., Yoo, J.-N., Lee, H. W., Kim, N. K., Yoo, H., Gee, M. S., Kim, J.-H., Seong, J., Inn, K., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105022 · Cited by 9
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9
Franco, R., Garrigós, C., Lillo, J., & Rivas‐Santisteban, R. (2024) · Cells · doi:10.3390/cells13151288 · Cited by 10
“The first attempts have failed due to serious side effects and/or a lack of efficacy [6,7], but more antibodies are entering clinical trials to look for efficacy without serious adverse effects.”
BackgroundWang, X., Zhao, M., Li, L., & Han, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.592024 · Cited by 10
“Amyloid pathology is defined as the initiating step of AD, which leads to subsequent tau deposition and neurodegeneration (Long and Holtzman, 2019); however, the well-established and validated biomarkers for brain amyloidosis detection, including cerebrospinal fluid (CSF) analysis and amyloid PET, are expensive, invas…”
BackgroundEzzati, A., Davatzikos, C., Wolk, D., Hall, C. B., Habeck, C., & Lipton, R. (2022) · Alzheimer's & Dementia · doi:10.1002/trc2.12223 · Cited by 8
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 9
Wellman, S. M., Coyne, O., Douglas, M. M., & Kozai, T. D. Y. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/aceca5 · Cited by 8
“Finally, previous and current FDA-approved clinical trials have focused on improving cognitive and behavioral outcomes in AD by using monoclonal antibodies to target and promote clearance of Aβ plaques from the brain, yet the results have either been mixed or unsuccessful thus far [17, 73].”
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI
Prato, F. S., Pavlosky, W. F., Foster, S. C., Thiessen, J. D., & Beaujot, R. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180098 · Cited by 11
“There is mounting evidence that once disease specific atrophy is detected it is too late for the initiation of treatment for neurodegenerative conditions [22, 83, 84].”
BackgroundAlzheimer’s Disease and Dementia
Lewis, P. A., & Spillane, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811069-0.00002-1 · Cited by 11
Iron Responsive Element (IRE)-mediated responses to iron dyshomeostasis in Alzheimer’s diseasePreprint
Hin, N., Newman, M., Pederson, S., & Lardelli, M. T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.01.071498 · Cited by 9
“With the failure of numerous recent amyloid beta-focused drug trials [1–4] it has become increasingly important to explore other factors contributing to the disease.”
BackgroundClinical outcome-guided deep temporal clustering for disease progression subtyping
Wang, D., Ma, X., Schulz, P. E., Jiang, X., & Kim, Y. (2024) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2024.104732 · Cited by 10
Zhang, K., Yang, K., Yu, G., & Shi, B. (2024) · Current Alzheimer Research · doi:10.2174/0115672050353736241218054012 · Cited by 8
“For instance, numerous phase III clinical trials have demonstrated that A β inhibitors do not significantly enhance cognitive function in AD patients [6-8].”
Malcangi, G., Marinelli, G., Inchingolo, A. D., Trilli, I., Ferrante, L., Casamassima, L., Nardelli, P., Inchingolo, F., Palermo, A., Inchingolo, A. M., et al. (2025) · Metabolites · doi:10.3390/metabo15060389 · Cited by 9
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 11
Apolipoprotein E4 in Alzheimer’s Disease: Role in Pathology, Lipid Metabolism, and Drug Treatment
Al-Ghraiybah, N. F., Alkhalifa, A. E., Itokazu, Y., Farr, T., Pérez, N., Ali, H., & Kaddoumi, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021004 · Cited by 11
“Solanezumab was assessed in three Phase III EXPEDITION trials, including over 3300 patients, with 66–69% being ApoE4 carriers [113].”
Olson, M. N., Dawes, P., Murray, L. F., Barton, N., Sundstrom, J., Orszulak, A. R., Chigas, S. M., Tran, K., Aylward, A. J., Caliandro, M. F., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00066-y · Cited by 7
“In parallel, we used the solanezumab antibody that selectively binds to monomeric A β and had failed to slow cognitive decline in people with preclinical AD or mild dementia 85,86 .”
Diagnosing Alzheimer’s Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe
Black, S. A. G., Stepanchuk, A. A., Templeton, G. W., Hernandez, Y., Ota, T., Roychoudhury, S., Smith, E. E., Barber, P. A., Ismail, Z., Fischer, K., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215402 · Cited by 8
Papiri, G., Luzzi, S., Marcucci, M., & Vignini, A. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2004107 · Cited by 9
“human subjects they have been shown to bind and demolish amyloid plaques effectively, while conflicting results have been obtained about their effectiveness on cognitive impairment [26, 27].”
BackgroundDisease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.